In the final installment of this 4-part series, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss the clinical value of enhanced cystoscopic imaging technologies and the operational barriers that may limit broader adoption in NMIBC care.
In part 3 of this 4-part series, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss practical strategies for communicating with pathologists when CIS is not clearly addressed in NMIBC pathology reports.
In part 2 of this 4-part series, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, examine how collaboration among urologists and pathologists, along with renewed attention to bladder mapping techniques, may improve CIS detection in NMIBC.
In this opening segment, Ravi D. Chauhan, MD, FACS, and R. Jonathan Henderson, MD, discuss how underreporting of CIS in pathology reports may limit access to guideline-supported therapies for patients with NMIBC.
Charles R. Powell, MD, highlights 12-month data on the Neuspera System for urge urinary incontinence, reflecting on ideal candidates and the treatment's role alongside other SNM options.
Martin Gleave, MD, FRCSC, FACS, explains how the adaptive, biomarker-driven GUNS trial uses neoadjuvant therapy to link genomic subtypes with treatment response.
Advances in laser technology, morcellator design, and anesthetic approach have substantially improved HoLEP efficiency and patient recovery over the past decade, while surgeon-owned procedural checklists and pre-morcellation hemostasis remain the most critical safety practices for avoiding morcellator injury.
Jennifer U. Miles-Thomas, MD, MBA, reflects on the key pillars to building successful surgeon/advanced practice providers partnerships.
In the FIT-001 trial, the combination of darlifarnib and cabozantinib demonstrated promising early antitumor activity in patients with ccRCC who had previously progressed on cabozantinib.
Song Jiang, MD, discusses evolving biomarker approaches that may redefine care in NMIBC.
Song Jiang, MD, PhD, discusses the balance between efficacy and safety data when considering the role for BCG/ICI combinations in BCG-naive NMIBC.
Charles R. Powell, MD, discusses how the rise of GLP-1–associated weight loss may influence outcomes and device management in sacral neuromodulation.
Akanksha Mehta, MD, MS, discusses why the updated vasectomy guideline expands its focus on fertility restoration, emphasizing patient counseling on reversal and individualized decision-making for future family building.
Adanma Ayanambakkam, MD, MS, discusses the FIT-001 trial and early findings on the safety profile for darlifarnib plus cabozantinib in ccRCC.
Helen L. Bernie, DO, MPH, discusses how expanded TRT labeling could improve care for men with idiopathic hypogonadism.
Nannan Thirumavalavan, MD, reflects on how the FDA’s testosterone labeling changes, informed by the TRAVERSE trial, have influenced TRT prescribing and clinician confidence over the past year.
Daniel J. George, MD, highlights survey findings on the role of caregivers in the treatment journey for patients with metastatic prostate cancer.
In this video, Dalia Kaakour, MD, MPH, highlights retrospective findings on the use of ctDNA in detecting residual disease and recurrence in testicular cancer.
In this video, Meri-Margaret Deoudes discusses ongoing challenges for patients with bladder cancer, including costs of care, delayed diagnoses among women, and access barriers among patients in rural areas.
Suction-enabled URS platforms and AI-driven prediction and planning tools represent 2 parallel frontiers in kidney stone management, with active fragment evacuation already in clinical use and artificial intelligence poised to reshape preoperative planning, patient selection, and intraoperative guidance.
David R. Wise, MD, PhD, discusses the potential for pasritamig combined with docetaxel to improve outcomes in patients with mCRPC.
Robert Flavell, MD, PhD, and Anil P. Bidkar, PhD, discuss the synergistic potential of CD46-directed alpha radiation and ADC therapy combination.
Akanksha Mehta, MD, MS, discusses AUA guideline recommendations for performing post-vasectomy semen analysis.
Neha Vapiwala, MD, FASTRO, discusses the integration of radiation therapy with systemic treatment intensification across different stages of localized and locally advanced prostate cancer.
Experts discuss the implications of the FDA’s potential pathway to expand testosterone replacement therapy labeling for low libido in men with idiopathic hypogonadism.
Kyle M. Rose, MD, discusses key considerations for optimizing the timing and sequencing of inguinal and pelvic lymph node dissection.
Akanksha Mehta, MD, MS, discusses updated recommendations from the 2026 AUA Vasectomy Guideline on vas isolation and occlusion techniques.
Fred Saad, MD, FRCS, discusses findings from a post hoc analysis of the phase 3 ARANOTE trial.
Medtronic's Touch Surgery enterprise platform, integrated with the Hugo robotic system, offers AI-driven case segmentation, real-time anatomic overlay, and two-way telementoring capabilities that James R. Porter, MD, describes as the most robust digital offering currently available on a robotic surgery platform.
Meri-Margaret Deoudes discusses findings from BCAN's New Faces of Bladder Cancer Report.
